These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 17266042

  • 1. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
    Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD.
    Int J Cancer; 2007 May 01; 120(9):1874-82. PubMed ID: 17266042
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD.
    Mol Cancer Res; 2009 Nov 01; 7(11):1882-92. PubMed ID: 19861407
    [Abstract] [Full Text] [Related]

  • 4. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M.
    Cell Signal; 2014 May 01; 26(5):1021-9. PubMed ID: 24463007
    [Abstract] [Full Text] [Related]

  • 5. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B.
    Int J Clin Exp Pathol; 2015 May 01; 8(6):6143-56. PubMed ID: 26261492
    [Abstract] [Full Text] [Related]

  • 6. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD.
    Breast Cancer Res; 2005 May 01; 7(5):R708-18. PubMed ID: 16168116
    [Abstract] [Full Text] [Related]

  • 7. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J, Lee J, Kim C, Choi J, Kim A.
    Tumour Biol; 2016 May 01; 37(5):5811-9. PubMed ID: 26581908
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.
    Cancer Res; 2009 Nov 01; 69(21):8403-11. PubMed ID: 19826038
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N, Pust S, Sandvig K.
    Biochim Biophys Acta; 2014 Sep 01; 1843(9):1987-96. PubMed ID: 24747692
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
    Aurisicchio L, Marra E, Luberto L, Carlomosti F, De Vitis C, Noto A, Gunes Z, Roscilli G, Mesiti G, Mancini R, Alimandi M, Ciliberto G.
    J Cell Physiol; 2012 Oct 01; 227(10):3381-8. PubMed ID: 22213458
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
    Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI.
    Endocrinology; 2003 Mar 01; 144(3):1032-44. PubMed ID: 12586780
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.
    Chen J, Ren Q, Cai Y, Lin T, Zuo W, Wang J, Lin R, Zhu L, Wang P, Dong H, Zhao H, Huang L, Fu Y, Yang S, Tan J, Lan X, Wang S.
    Biochem Biophys Res Commun; 2018 Jun 18; 501(1):212-219. PubMed ID: 29715459
    [Abstract] [Full Text] [Related]

  • 19. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
    Sak MM, Szymanska M, Bertelsen V, Hasmann M, Madshus IH, Stang E.
    Carcinogenesis; 2013 Sep 18; 34(9):2031-8. PubMed ID: 23698633
    [Abstract] [Full Text] [Related]

  • 20. Role of erbB3 receptors in cancer therapeutic resistance.
    Lee Y, Ma J, Lyu H, Huang J, Kim A, Liu B.
    Acta Biochim Biophys Sin (Shanghai); 2014 Mar 18; 46(3):190-8. PubMed ID: 24449784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.